To Evaluate the Safety and Efficacy of a Single-Use IVUS Ablation for Primary Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

213 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-02-25

Study Completion Date

2029-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, multicenter, blinded, randomized controlled clinical trial designed to evaluate the safety and efficacy of a single-use intravascular ultrasound ablation catheter and ultrasound ablation system in the treatment of primary hypertension.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Modulated Ultrasound Renal Denervation for HTN

NCT06877221

Refractory Hypertension or Drug-intolerant Hypertension

RECRUITING NA

Renal Denervation With Sterile Irrigated Deflectable Ablation Catheter Used in Renal Artery in Primary Hypertension

NCT03511313

Primary Hypertension

UNKNOWN NA

Randomized Comparison of Ultrasound Versus Radiofrequency Denervation in Patients With Therapy Resistant Hypertension

NCT02920034

Therapy Resistant Hypertension

COMPLETED NA

Sympathetic Mapping/ Ablation of Renal Nerves Trial

NCT02761811

Hypertension

ACTIVE_NOT_RECRUITING NA

Safety and Efficacy of Modulated Ultrasound Renal Denervation for HTN（FIM）

NCT06877234

Essential Hypertension

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This trial adopts a prospective, multicenter, randomized controlled design to validate the safety and efficacy of a single-use intravascular ultrasound ablation catheter and ultrasound ablation system in the treatment of primary hypertension. Subjects who signed the informed consent form will enter the screening phase and undergo a run-in period for 4-week of standardized medication regimen. Specifically, their current antihypertensive treatment will be uniformly replaced with a combination of an angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB) (Valsartan/Amlodipine 80:5 mg) or a triple combination of ARB/CCB (Valsartan/Amlodipine 80:5 mg) plus a diuretic (Hydrochlorothiazide 12.5mg) . If the subject's office systolic blood pressure (SBP) ≥180 mmHg or diastolic blood pressure (DBP) ≥110 mmHg during the run-in period, the investigator may adjust the medication and restart a run-in period of ≥28 days. Blood pressure will be re-evaluated, and subjects failed to meet the inclusion criteria after adjustment will be excluded.

Subjects meeting the inclusion criteria and not violating exclusion criteria will be randomized in a 2:1 ratio to either the treatment group or the control group. The treatment group will undergo intravascular ultrasound ablation therapy, while the control group will only undergo renal artery angiography. Both groups will maintain the standardized medication regimen for 6 months post-procedure (if a subject's office SBP exceeds 180 mmHg or drops below 110 mmHg in three consecutive measurements spaced 1 hour apart, the investigator may adjust the medication and record their blood pressure before the adjustment).

The primary efficacy endpoint is the change in 24-hour average ambulatory systolic blood pressure at 6 months post-procedure. Results will be analyzed using a superiority testing hypothesis to demonstrate that the treatment group achieves significantly greater reduction in 24-hour mean ambulatory systolic blood pressure compared to the control group at 6-month follow-up. During follow-up, office blood pressure, 24-hour ambulatory blood pressure, medication usage, safety events, and adverse events will be recorded for both groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Essential Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Renal denervation (RDN) Group

Receive standardized treatment with a minimum of two drugs and renal denervation treatments (RDN)

Group Type EXPERIMENTAL

Intravascular Ultrasound Ablation Therapy

Intervention Type PROCEDURE

The single-use intravascular ultrasound ablation catheter is used in conjunction with the ultrasound ablation device to remove renal sympathetic nerves.

Standardized medication regimen.

Control Group

Receive standardized treatment with a minimum of two drugs and renal artery angiography only

Group Type SHAM_COMPARATOR

Renal Artery Angiography

Intervention Type PROCEDURE

Only undergo renal artery angiography. Standardized medication regimen.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intravascular Ultrasound Ablation Therapy

The single-use intravascular ultrasound ablation catheter is used in conjunction with the ultrasound ablation device to remove renal sympathetic nerves.

Standardized medication regimen.

Intervention Type PROCEDURE

Renal Artery Angiography

Only undergo renal artery angiography. Standardized medication regimen.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Aged ≥18 years and ≤75 years, regardless of gender.
2. Documented history of primary hypertension.
3. Stable use of at least two antihypertensive medications for a minimum of 4 consecutive weeks prior to randomization, specifically requiring a combination of an angiotensin II receptor blocker (ARB) and a calcium channel blocker (CCB) or a triple combination of ARB/CCB plus a diuretic agent . After at least 4 consecutive weeks of screening, blood pressure must meet the following criteria:

1. Office systolic blood pressure (SBP) ≥150 mmHg and \<180 mmHg;
2. Office diastolic blood pressure (DBP) ≥90 mmHg;
3. 24-hour ambulatory systolic blood pressure ≥135 mmHg and \<170 mmHg.
4. Patients who can understand the purpose of the trial, voluntarily participate and sign the informed consent form, and are willing to comply with clinical follow-up.

Exclusion Criteria

1. Unsuitable Renal Artery Anatomy for Treatment

1. Main renal artery diameter \<4 mm or length \<20 mm.
2. Accessory renal artery diameter ≥ 2 mm and \<4 mm.
3. Renal artery stenosis \>50% in the main renal artery.
4. Renal artery aneurysm, fibromuscular dysplasia, or severe calcification.
5. Presence of a renal artery stent.
6. Single kidney.
2. Estimated Glomerular Filtration Rate (eGFR) \<45 mL/min/1.73 m².
3. Diagnosis of Type 1 Diabetes Mellitus.
4. Orthostatic Hypotension.
5. Recent Vascular Events:Acute myocardial infarction, unstable angina, syncope, or cerebrovascular accident within 3 months prior to signing the informed consent form.
6. Suspected Secondary Hypertension.
7. Respiratory Support:a) Requirement for long-term oxygen support or mechanical ventilation (excluding nocturnal respiratory support for sleep apnea).
8. Prior Renal Artery Denervation Procedure.
9. Life Expectancy \<1 Year.
10. Pregnancy, Lactation, or Plans to Become Pregnant Within 6 Months (for Females); Males Planning to Conceive Within 6 Months.
11. Current Participation in Another Clinical Trial Without Completion of the Primary Endpoint.
12. Allergy to Contrast Agents.
13. Other Reasons Deemed by the Investigator to Make the Subject Unsuitable for Participation (e.g., Poor Compliance).

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.